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Objective. An association between therapeutic in-
hibition of tumor necrosis factor (TNF) and solid ma-
lignancies was observed during the Wegener’s Granulo-
matosis Etanercept Trial (WGET), which included 180
patients with granulomatosis with polyangiitis (Wegen-
er’s) (GPA). The present study was conducted to deter-
mine the malignancy risk beyond the time of exposure to
study therapy.
Methods. The occurrence and type of solid malig-
nancies were ascertained using a standardized data
form. Data collected included vital status, histologic
findings, and therapeutic interventions. The Surveil-
lance, Epidemiology, and End-Results database was
used to estimate a standardized incidence rate (SIR) for
solid malignancies.
Results. Post-trial followup data were available
for 153 patients (85% of the original cohort), with a
median followup time of 43 months. Fifty percent of
these patients had received etanercept. There were no
differences in demographic characteristics between the
etanercept and placebo groups. Thirteen new solid
malignancies were detected, 8 in the etanercept group
and 5 in the placebo group. Compared to the general
population, the risk of solid malignancies in the etan-
ercept group was increased (SIR 3.92 [95% confidence
interval 1.69–7.72]), but was not different from the risk
in the placebo group compared to the general popula-
tion (SIR 2.89 [95% confidence interval 0.94–6.73]). All
solid malignancies occurred in patients who had been
exposed to cyclophosphamide. The overall duration of
disease and a history of malignancy before trial enroll-
ment were associated with the development of malig-
nancy during post-trial followup.
Conclusion. The incidence of solid malignancy
remained increased during long-term followup of the
WGET cohort. However, this could not be attributed
solely to etanercept exposure during the trial. Anti-TNF
therapy with etanercept appears to further increase the
risk of malignancy observed in patients with GPA
treated with cytotoxic agents and should be avoided in
these patients.
Owing to the importance of tumor necrosis factor
 (TNF) in the mechanisms of inflammation, TNF
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blockers have been widely used for the treatment of
immune-mediated chronic inflammatory diseases. How-
ever, the first property ascribed to TNF was its ability
to induce necrosis of sarcomas and other skin-
transplanted cancers (1). TNF also may play a role in
immunosurveillance against cancer cells by causing cy-
tostasis and cytolysis (2), inducing neoplastic cells to
undergo apoptosis (3,4), and inhibiting tumor-associated
angiogenesis (5,6). There has been a longstanding con-
cern that TNF blockade might facilitate the develop-
ment of neoplasia de novo or the progression of prema-
lignant and established malignant lesions by interfering
with the normal physiologic effects of TNF that control
tumor growth.
The relationship between TNF blockade treat-
ment and malignancy has been studied in rheumatoid
arthritis (RA), other inflammatory arthropathies, and
Crohn’s disease. However, these investigations have
been complicated by the increased incidence of malig-
nancies already observed in many of those diseases
(7–14) and by possible channeling bias (i.e., patients with
severe disease, who show the highest disease-associated
risk of malignancy, are more likely to be treated with
biologic agents than patients with milder forms of the
disease) (15). TNF blockade treatment has been linked
to the development of lymphoma, notably hepatosplenic
T cell lymphoma in juvenile inflammatory arthritis and
Crohn’s disease, which otherwise occurs only rarely (16).
In contrast, the association of TNF blockade with solid
malignancies remains uncertain (16–21).
For granulomatosis with polyangiitis (Wegener’s)
(GPA) and microscopic polyangiitis (MPA), the malig-
nancy risk associated with TNF blocker use has been
even more difficult to estimate because of the low
prevalence of these diseases and the paucity of data on
TNF blocker use in GPA and MPA. Furthermore,
several reports have suggested an increased risk of both
solid and hematologic malignancies in GPA and MPA
per se, with estimates of global risk ranging from 1.6-fold
to 18-fold compared to the general population (22–24)
or to patients with other rheumatologic conditions
(25,26). In the Wegener’s Granulomatosis Etanercept
Trial (WGET), a placebo-controlled trial in which etan-
ercept or placebo was given in addition to standard
therapy for remission induction and maintenance in
GPA (27), solid malignancies were observed only among
patients treated with etanercept who had also been
exposed to cyclophosphamide (CYC), with an observed
standardized incidence ratio (SIR) of 3.1 (95% confi-
dence interval [95% CI 1.1–6.8]) (28). This finding led to a
warning by the manufacturer of etanercept against the
concomitant use of etanercept and CYC under any circum-
stances and against its use in conjunction with any other
immununosuppressive agent for the treatment of GPA.
To further investigate the relationship between
etanercept therapy and malignancy, we conducted a
followup study to identify and characterize any new
cases of solid malignancies that arose in the WGET
cohort during the 5-year period after completion of
study treatment. We report the results herein.
PATIENTS AND METHODS
The cohort of patients originally enrolled into the
WGET formed the basis of this analysis. The design of the
WGET, the clinical characteristics of the patients enrolled, and
the treatment outcomes have been described in detail previ-
ously (27,29,30). Briefly, 180 patients who met at least 2 of the
5 modified American College of Rheumatology criteria for the
classification of GPA (29,31,32) were randomized 1:1 to
receive either etanercept 25 mg subcutaneously twice weekly
or placebo in addition to standard remission induction and
maintenance therapy for GPA. Patients were eligible for
enrollment if they had active disease with a modified Birming-
ham Vasculitis Activity Score modified for GPA (32) of 3 as
a result of newly diagnosed disease or a relapse. Patients who
had been diagnosed as having a malignancy within 5 years prior
to the screening for trial eligibility, except those with squamous
or basal cell carcinomas of the skin or cervical carcinoma in
situ who had received curative surgical therapy, were excluded
from participation.
Data were obtained for this study in the context of a
long-term followup study of the WGET cohort. The occur-
rence and the type of malignancy after the common closeout
(September 2003) were ascertained by investigators in 2007–
2008, using a standardized data form. Most patients continue
to be followed up regularly at the original WGET site, and the
information was obtained by the physician who was in direct
contact with the WGET participants and/or by reviewing the
medical records. If the patient was no longer being regularly
followed up at the WGET site, the data form was completed by
telephone interview with the patient.
The diagnosis of cancer was confirmed in all cases by
reviewing the histopathologic reports. Therapy for GPA was
recorded for each of these cases, focusing on type and dose of
immunosuppressive agents received before and during the
clinical trial, as well as after the trial closeout. Vital status at
the time of last contact was recorded, including the date of
death if applicable.
Descriptive statistical analyses were performed to an-
alyze the development of malignancies during the trial, after
completion of the trial (post-trial followup), and both periods
combined (followup from trial entry). Exploratory analyses
comparing patients who developed solid malignancies versus
those who did not were performed using Pearson’s chi-square
test or Fisher’s exact test for categorical variables, and Wil-
coxon’s rank sum test for continuous variables. Data were
expressed as the mean  SD or the median (range).
Using the Surveillance, Epidemiology, and End-
Results (SEER) database (Surveillance Research Program,
National Cancer Institute) and SEER*stat software version
6.3.6, the age- and sex-adjusted incidence rates of solid malig-
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nancies in the US population between the years 2000 and 2004
(excluding leukemia, lymphoma, myeloma, and nonmelanoma
skin cancers) were determined. This incidence corresponds to
the expected rate of solid malignancy for the purpose of this
comparison. The incidence rate for malignancies in our cohort
was calculated by dividing the number of events by the total
patient-years of observation (observed cases). The SIRs
([observed/expected cases]  100) for solid malignancies with
the respective 95% CIs were calculated.
The SIRs were compared between groups (etanercept
versus placebo) using an approximate F test for comparing
Poisson variates. With data censored at last followup for
subjects without malignancies, the cumulative incidence of
malignancies over time following the treatment period was also
estimated (using the Kaplan-Meier method) and was com-
pared between groups by log rank test.
RESULTS
Demographic characteristics of the patients in
the cohort. Post-trial followup information was available
for 153 of the 180 WGET participants (85%) (Figure 1
and Table 1). The median time of followup was 43
months from the common closeout date. Seventy-seven
of these patients (50.3%) had been assigned to receive
Figure 1. Schematic diagram of deaths and solid malignancies (SM) observed during followup of patients in the
Wegener’s Granulomatosis Etanercept Trial (WGET). a  death caused by solid malignancy diagnosed during the trial.
b  deaths caused by solid malignancy diagnosed after the trial (n  2), leukemia diagnosed after the trial (n  1),
myocardial infarction (n  1), or indeterminate cause (n  3). c  deaths caused by solid malignancy diagnosed after
the trial (n  2), sepsis (n  2), renal failure (n  1), arrhythmia (n  1), or indeterminate cause (n  2).
Table 1. Demographic characteristics of the 153 GPA patients fol-










Male sex 50 (65) 44 (58) 94 (61)
Age, mean  SD years
At trial enrollment 52  14 49  17 50  15
At last contact 57  14 54  17 55  15
Race
White, non-Hispanic 69 (90) 72 (95) 141 (92)
Black, non-Hispanic 2 (2.5) 0 (0) 2 (1)
Hispanic 4 (5) 2 (2.5) 6 (4)
Other 2 (2.5) 2 (2.5) 4 (3)
Alive at end of present study 65 (84) 66 (87) 131 (86)
Previous history of cancer 12 (16) 5 (7) 17 (11)
Family history of cancer 15 (19) 14 (18) 29 (19)
Tobacco use
Current use 1 (1) 1 (1) 2 (1)
Previous use 22 (29)† 10 (13) 32 (21)
* Except where indicated otherwise, values are the number (%).
GPA  granulomatosis with polyangiitis (Wegener’s); WGET 
Wegener’s Granulomatosis Etanercept Trial.
† P  0.015 versus placebo group.
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etanercept in the WGET and 76 (49.7%) to receive
placebo. Sex distribution, age, race, vital status, previous
personal or family history of cancer, or current tobacco
use did not differ between the etanercept and the
placebo groups; only past tobacco use was more com-
mon among patients who had received etanercept (29%
versus 13%; P  0.015).
Solid malignancies diagnosed since WGET close-
out. Thirteen new solid malignancies, in 13 of the 153
patients (8.5%), were diagnosed during the post-trial
followup period. The types of cancer and the clinical
characteristics of the affected patients are summarized
in Table 2. The median time to cancer diagnosis was 52
months after trial enrollment (range 31–78 months ) and
26 months after the common closeout date (range 3–45
months). The 4 deaths (2 from each treatment group)
that occurred during the post-trial followup all resulted
from the cancer.
All of the solid malignancies diagnosed during
the post-trial period occurred in patients who had re-
ceived cyclophosphamide (CYC) before, during, or after
the trial (n  138). Twelve of the 13 patients had
received at least 1 additional immunosuppressive agent
(azathioprine, methotrexate, or cyclosporin A). The
median cumulative dose of CYC was 56 gm (range
1–264) prior to enrollment and 16 gm (range 7–50)
during the trial. For the post-trial period, we were able
to ascertain the approximate duration of CYC exposure
in the individual patients but could not quantify the
cumulative doses.
Risk factors for the development of solid malig-
nancies after WGET closeout. We compared the char-
acteristics of the 13 patients who developed solid malig-
nancies after the trial closeout date with those of the 140
patients who did not develop a solid malignancy (Table
3). There were no significant differences between the
groups in terms of treatment assignment, age, sex, or
extent of disease at trial enrollment. However, the
prevalence of disease relapse at the time of trial enroll-
ment was greater among the patients who developed
solid malignancies (85% versus 54%; P  0.04). This
group also had a longer mean disease duration, as
assessed by either time from symptom onset to trial
enrollment (mean  SD 6.4  3.9 years versus 3.3  4.8
years; P  0.001) or time from diagnosis to trial enroll-
ment (5.1  4.4 years versus 2  3.8 years; P  0.0006).
Similar differences were found when the times between
symptom onset and end of followup or between diagno-
sis and end of followup were analyzed in both groups
(data not shown). Importantly, the group of patients who
developed a solid malignancy after trial closeout also
had a higher frequency of malignancy before entering
the trial (31% versus 9%; P  0.03).
Relationship between treatment assignment and
risk of solid malignancy during WGET followup. Table
4 shows the observed and expected number of patients
with solid malignancy and the calculated SIRs for the
etanercept and placebo groups. The analysis is presented
for 3 periods: the trial period (from enrollment until the
common closeout in September 2003), the post-trial
period (from common closeout until last visit or death,
representing the focus of the present study), and the
overall period (trial and post-trial periods combined).
During the trial, the frequency of solid malignancies was
higher in the etanercept group than in the placebo group
(7% versus 0%; P  0.01) (28). However, during the
post-trial period, the frequency of solid malignancies
was not different between the etanercept and placebo
groups (10% versus 7%; P  0.39), although the fre-
quency was numerically higher in the etanercept group.
When the 2 periods were combined, the overall fre-
quency of solid malignancies from time of trial enroll-
ment remained higher in the etanercept group (18%)
compared to the placebo group (7%) (P  0.03).
To account for variations in age, sex, and dura-
tion of followup, SIRs were calculated for each treat-
ment group and period (Table 4). For the trial period,
the SIR for solid malignancies in the etanercept group
was 3.8 (95% CI 1.39–8.26), compared to 0 (95% CI
0–3.63) in the placebo group. These values differ numer-
ically from those previously reported (SIR in etanercept
group 3.12 [95% CI 1.15–6.8]) (28) because the refer-
ence population was extended for the present analysis to
include the last year with available data in the SEER
database. For the post-trial period, the SIR for solid
malignancies in the etanercept group was not signifi-
cantly different from that in the placebo group (3.92
[95% CI 1.69–7.72] and 2.89 [95% CI 0.94–6.73], respec-
tively; P  0.597). For the combined period, the SIR was
3.76 (95% CI 2.05–6.31) in the etanercept group and
1.71 (95% CI 0.56–3.99) in the placebo group (P 
0.117). A time-to-event analysis comparing treatment
groups confirmed that the occurrence of malignancies
post-trial did not differ between treatment arms (P 
0.44).
We also evaluated whether exposure to other
TNF blockers had an effect on the malignancy rate.
Sixteen patients (8 in each WGET treatment group)
received infliximab after discontinuation of experimen-
tal therapy. One of these patients, assigned to the
placebo group, developed a solid malignancy that was
previously reported (27). We reanalyzed the SIRs in 2
ways: 1) by excluding from analysis all 16 patients
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exposed to infliximab, and 2) by reclassifying the
infliximab-exposed patients from the placebo group to
the etanercept group. Neither analysis resulted in a
meaningful change in the SIRs or a significant difference
in the malignancy rates between TNF blocker–exposed
versus nonexposed patients, for any of the observation
periods (data not shown).
DISCUSSION
This long-term followup study of the WGET
cohort showed that in comparison to the general popu-
lation, the increased risk of solid malignancies observed
in the etanercept group during the trial persisted during
post-trial followup. However, in contrast to the trial





(n  140) P†
Treatment assignment 0.40
Etanercept 8 (10) 69 (90)
Placebo 5 (7) 71 (93)
Age, mean  SD years 57  13 50  16 0.07
Male/female 10 (77)/3 (23) 84 (60)/56 (40) 0.37
Limited/severe disease 5 (38)/8 (62) 42 (30)/98 (70) 0.54
Age at onset of vasculitis symptoms, mean  SD years 51  13 46  16 0.26
Relapsing disease 11 (85) 75 (54) 0.04
Duration since symptom onset, mean  SD years 6.4  3.9 3.3  4.8 0.001
Duration since diagnosis, mean  SD years 5.1  4.4 2  3.8 0.0006
History of cancer before trial‡ 4 (31) 12 (9) 0.03
Family history of cancer 0 (0) 29 (21) 0.13
Current tobacco use 0 (0) 5 (4) 1.0
Prior treatment with immunosuppressive drugs 11 (85) 80 (57) 0.08
Ever treated for GPA 13 (100) 125 (89) 0.37
CYC treatment (daily or intermittent)
Ever used§ 13 (100) 125 (89) 0.4
During WGET 8 (62) 113 (81) 0.13
MTX treatment (oral or SC or IM)
Ever used§ 9 (69) 82 (59) 0.56
During WGET 11 (85) 110 (79) 1.0
AZA treatment
Ever used§ 7 (54) 49 (35) 0.23
During WGET 4 (31) 45 (32) 1.0
* Except where indicated otherwise, values are the number (%). “Baseline” refers to the time of enrollment in the WGET. SC  subcutaneous; IM 
intramuscular (see Table 2 for other definitions).
† By chi-square or Fisher’s exact test for categorical data, and by Wilcoxon’s rank sum test for continuous data.
‡ In the solid malignancy group, bladder cancer (1 patient), breast cancer (1 patient), melanoma and basal cell carcinoma (1 patient), and skin
cancer (1 patient). In the no solid malignancy group, basal cell carcinoma (4 patients), colon cancer (3 patients), breast cancer (1 patient),
lymphoma (1 patient), precancerous or cancerous skin lesion (1 patient), prostate cancer (1 patient), and rectal and skin cancer (1 patient).
§ Before trial enrollment, during trial, or after trial.
Table 4. Frequency of observed and expected solid malignancy events, and SIRs*
Followup period
(median duration)










expected SIR (95% CI)
Frequency of
malignancy† SIR‡
Trial (30 months) 6 1.58 3.80 (1.39–8.26) 0 1.02 0 (0–3.63) 0.01 0.03
Post-trial (43 months) 8 2.04 3.92 (1.6–7.72) 5 1.73 2.89 (0.94–6.73) 0.39 0.60
From trial entry (64 months) 14 3.73 3.76 (2.05–6.31) 5 2.92 1.71 (0.56–3.99) 0.03 0.12
* SIRs  standardized incidence ratios; 95% CI  95% confidence interval.
† By Fisher’s exact test.
‡ By F test.
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period, solid malignancies were also observed in the
placebo group during post-trial followup. Furthermore,
there was no significant difference in SIRs between the
etanercept and placebo groups. Other factors associated
with the development of solid malignancies in the
WGET cohort were recognized, particularly the dura-
tion of disease and history of malignancy prior to trial
enrollment. This suggests that after discontinuation of
etanercept, the malignancy risk conferred by this agent
in GPA reverts back to the increased baseline risk
inherent to the disease and its treatment. As the dura-
tion of disease is linked to duration of therapy and all
solid malignancies that occurred in this cohort devel-
oped after CYC exposure, our results further highlight
the need for safer treatment regimens, especially ones
that reduce or eliminate exposure to CYC.
During the time period of the WGET, all solid
malignancies that developed occurred in the etanercept
group (28). In contrast, new malignancies observed
during the post-trial followup were diagnosed in patients
from both treatment arms (Table 4). The risk of solid
malignancies remained significantly increased for pa-
tients in the etanercept group compared with risk in the
general population (based on the SEER database).
However, the relative risk in the placebo group com-
pared to the general population was of similar magni-
tude. Thus, with longer time from exposure to etaner-
cept, other risk factors become relatively more
important.
In our study, the SIR for solid malignancies in the
etanercept group during the followup from trial entry
(trial and post-trial period) was 3.76 (95% CI 2.05–6.31),
an estimated risk that was higher than the risks among
non–TNF blockade–treated patients with antineutrophil
cytoplasmic antibody–associated vasculitis reported by
Westman et al (standardized morbidity ratio 1.6 [95%
CI 0.9–2.7]) (23), Knight et al (SIR 2.0 [95% CI 1.7–2.5])
(24), and Faurschou et al (SIR 2.1 [95% CI 1.5–2.7])
(33). The risk observed in these 3 earlier studies was
similar to the SIR in the placebo group of the WGET
cohort (1.71 [95% CI 0.56–3.99]). These earlier studies
are comparable to ours in that they also used healthy
populations as the reference and determined risk esti-
mates based on incidence. In contrast, our estimate of
risk was lower than those reported by Tatsis et al (odds
ratio 18 [95% CI 2.3–140]) (25) and Pankhurst et al
(relative risk 6.0 [95% 3.7–9.7]) (26). The latter 2 studies
are not as easily comparable to ours because their
reference populations consisted of patients with auto-
immune diseases (systemic lupus erythematous and RA,
respectively) rather than healthy populations, and their
estimates were based on the frequency of solid malig-
nancies in the studied groups, rather than the incidence.
In the context of this literature, the SIRs observed in our
study suggest that etanercept boosts the already in-
creased background risk of malignancies in patients with
GPA for the duration of exposure to etanercept, but not
much beyond the time of exposure.
There is ample epidemiologic evidence and
mechanistic experimental support linking chronic in-
flammation to the development of cancer (34). For
autoimmune disease in general, it has been speculated
that both immune dysregulation inherent to the under-
lying disease and the reduction of immunosurveillance
caused by immunosuppressive therapy promote malig-
nancy (35,36). An association between duration of RA
and risk of malignancy (lymphoma) has long been
suspected, and evidence linking the malignancy risk to
disease activity and severity of RA has emerged (11,37–
40).
There is currently no clear evidence that vasculi-
tis per se confers an increased risk of malignancy.
Among patients with giant cell (temporal) arteritis,
which is not treated with CYC, no increased malignancy
risk was found (41). In GPA, the development of
urothelial malignancies has been clearly linked to ther-
apy with CYC, and one recent epidemiologic study
showed that the overall cancer risk in GPA is linked to
the cumulative CYC exposure (33,42). Of note, in the
present study at least 10 of the 13 patients who devel-
oped solid malignancies after trial closeout had received
36 gm of CYC (Table 2), a cumulative dose that has
been identified as critical for the development of malig-
nancies in GPA (42).
In our cohort, duration of disease and history of
previous malignancy emerged as risk factors for the
development of solid malignancy. The greater number of
different cytotoxic drugs used and greater cumulative
CYC exposure in the group of patients with solid
malignancies did not reach statistical significance when
compared to those who did not develop malignancy
(Table 3). However, these factors cannot be separated
from disease duration.
The risk of cancer induction by etanercept has
been studied extensively in chronic arthropathies, in
which the drug has been used widely. An association
with hematologic malignancies has been suggested, but
estimation of the risk is difficult as these autoimmune
diseases by themselves have an increased risk of malig-
nancy (especially lymphomas) (12,43,44). In contrast, no
etanercept-associated risk of solid malignancy has been
found to date in other autoimmune diseases (45,46).
However, unlike patients with GPA, patients with RA or
other arthropathies are usually not treated with CYC.
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The malignancies observed in the WGET cohort
include a variety of histopathologic types and organs of
origin. The fact that 3 of the 19 solid malignancies
diagnosed after enrollment in the WGET (2 in patients
from the etanercept group and 1 in a patient from the
placebo group) were cholangiocarcinomas is an unex-
pected finding, owing to the rarity of this neoplasm in
the general population.
Our study has several important strengths. The
study cohort consisted of well-characterized patients
with a single disease, GPA. The exclusion of patients
who had a solid malignancy within 5 years prior to
enrollment, as well as the temporal relationship between
the diagnosis of GPA and the development of cancer,
make it unlikely that the vasculitis was a paraneoplastic
phenomenon in any of the patients (47). The demo-
graphic and clinical characteristics were similar in the
etanercept and placebo groups. Finally, the clinicians
caring for the study participants were aware of the
possible malignancy risk conferred by randomization to
receive treatment with etanercept (28) and of the in-
creased malignancy risk among patients with GPA, and
consequently these patients were monitored closely,
making it unlikely that any solid malignancies were
missed in this cohort.
The study also has limitations. First, followup
information could be obtained for only 85% of the
original cohort, possibly introducing some bias. How-
ever, the balance in the number of patients originally
assigned to receive etanercept versus those assigned to
receive placebo was maintained, and the high rate of
followup likely preserved the balance of risk factors
between the 2 groups (27). Second, the information
obtained during post-trial followup is less complete than
that obtained under the strict trial protocol; however, it
remains unlikely that any cancers were missed unless
they were asymptomatic. Third, the small number of
observed solid malignancies precluded a multivariate
analysis of risk factors contributing to malignancy devel-
opment.
In conclusion, the long-term post-trial followup
of the patients in the WGET cohort confirms that
patients with GPA are at increased risk for solid malig-
nancies. The increased risk in the etanercept group
compared to the general population observed during the
trial remained unchanged during post-trial followup.
However, in contrast to the trial period, this increased
risk observed during post-trial followup could no longer
be attributed to an effect of etanercept, owing to the lack
of a significant difference in the frequency of malignan-
cies between the active treatment and placebo groups.
Rather, the increased risk for solid malignancy during
post-trial followup of this cohort seems to be related to
disease duration and history of previous malignancy.
Because of the potential interaction between anti-TNF
therapy and high CYC exposure in the development of
malignancy and the lack of demonstrable efficacy of this
regimen in GPA, it is reasonable to avoid the use of
etanercept in patients with GPA, particularly those with
a history of chronic relapsing disease, CYC exposure, or
previous malignancy.
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